Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Notes underwriting agrmnt
RADIENT PHARMACEUTICALS Corp (RXPC) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/06/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/18/2013 8-K/A Quarterly results
06/11/2013 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement with Uni Pharma Co., Ltd."
10/05/2012 8-K/A Entry into a Material Definitive Agreement, Other Events
09/18/2012 8-K/A Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Amendment to Agreement with Global Cancer Diagnostics, Inc."
08/24/2012 8-K/A Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment to Agreement with Global Cancer Diagnostics, Inc."
07/17/2012 8-K Form 8-K - Current report
06/26/2012 8-K Form 8-K - Current report
05/21/2012 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement with 2011 Noteholders"
04/30/2012 8-K Other Events
04/03/2012 8-K Form 8-K - Current report
03/28/2012 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
03/26/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/06/2012 8-K Regulation FD Disclosure, Other Events
02/29/2012 8-K Regulation FD Disclosure
02/23/2012 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
02/10/2012 8-K/A Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events
01/17/2012 8-K/A Form 8-K - Current report [amend]
12/01/2011 8-K Form 8-K - Current report
11/29/2011 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Agreement with Alpha Capital Anstalt",
"Agreement with Whalehaven Capital Ltd.",
"Exchange Agreement with the 2011 Note holders",
"Form of Certificate of Designations of the Series B Convertible Preferred Stock",
"Form of Convertible Note",
"Form of Series A Warrant",
"Form of Series B Warrant",
"Form of Certificate of Designations of the Series C Convertible Preferred Stock",
"Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital"
11/15/2011 8-K Form 8-K - Current report
11/07/2011 8-K Form 8-K - Current report
08/29/2011 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Settlement Agreement with Alpha and Whalehaven",
"Form of Note Issued to Alpha and Whalehaven",
"Form of Release between Alpha and Whalehaven",
"Form of Consent by the 2011 Noteholders to the Alpha/Whalehaven Settlement Agreement",
"Court Order",
"Letter Agreement with 2011 Noteholders"
08/22/2011 8-K Form 8-K - Current report
08/15/2011 8-K Quarterly results
Docs: "Radient Pharmaceuticals Announces FY 2011 Second Quarter Results"
08/02/2011 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Letter Amendment"
07/01/2011 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Certificate of Designations of Series A Convertible Preferred Stock",
"Exchange Agreement",
"Form of Notes",
"Form of Warrants",
"3(a)(10) Order"
06/23/2011 8-K Form 8-K - Current report
06/08/2011 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Radient Pharmaceuticals Announces FY 2011 First Quarter Results June 8, 2011/Marketwire – Radient Pharmaceuticals Corporation “RPC” , a developer and global marketer of In Vitro Diagnostic cancer tests, today announced the filing of its Form 10-Q for the first quarter ended March 31, 2011. “Radient is now putting into place a focused strategy to build sales of our IVD cancer diagnostics through multiple channels both domestically and internationally. Our domestic and international marketing strategies include seeking key distribution partners, as well as reaching out to doctors; public and private payers, including health insurance companies; key opinion leaders; and the medical and scientific community at large,” stated RPC’s CEO, Mr. Douglas MacLellan. “Internationally, we are working wi..."
06/02/2011 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
Docs: "RADIENT PHARMACEUTICALS ADDRESSES DEFAULT OF FY2010 NOTES June 1, 2011/Marketwire –Radient Pharmaceuticals Corporation , a developer and global marketer of In Vitro Diagnostic cancer tests, today announced it has filed an 8K with the Securities and Exchange Commission reporting it received an event of default notice from two of the note holders of private financings RPC completed between March 22, 2010 and April 26, 2010 pursuant to which such holders’ notes shall become immediately due and payable. RPC is currently negotiating a settlement with the two note holders who allege they are owed approximately $1,306,619 for their portion of the notes including principal, accrued interest and penalties. These two note holders submitted default notices to RPC demanding payment of the note in full..."
05/26/2011 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "Radient Pharmaceuticals Receives Non-Compliance Notice From NYSE AMEX May 26, 2011/Marketwire – Radient Pharmaceuticals Corporation “RPC” or the “Company” , a developer and global marketer of In Vitro Diagnostic cancer tests, announced today that RPC received a letter dated May 24, 2011 from NYSE Amex stating that because RPC did not file its first quarter report on Form 10‐Q for the quarter ended March 31, 2011 on or before May 23, 2011, RPC is not compliant with Sections 134 and 1101 of the Exchange’s Company Guide and has violated its listing agreement with the Exchange, pursuant to which the Exchange is authorized to suspend and remove RPC’s securities from the Exchange pursuant to Section 1003 of the Company Guide. Upon the occurrence of such noncompliance, the Exchange is requi..."
05/25/2011 8-K Form 8-K - Current report
05/24/2011 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "RADIENT PHARMACEUTICALS PROVIDES UPDATE REGARDING 2010 FORM 10K & FY 2011 Q1 10Q May 24, 2011/Marketwire – Radient Pharmaceuticals Corporation , a US-based company specializing in the research, development, and international commercialization of in vitro diagnostic cancer tests, announced today, that it intends to file its Annual Report on Form 10-K for the year ended December 31, 2010 after market today and anticipates filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 on or before the close of business on Tuesday, June 7, 2011. In the Form 10-Q, the Company expects to report revenues of approximately $31,000 and a net loss in the range of $10.6 – $12 million compared with net loss of approximately $2.6 million for the three months ended March 31, 2010. The Comp..."
05/17/2011 8-K/A Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "RADIENT PHARMACEUTICALS ANNOUNCES SETTLEMENT REACHED WITH FY2009 Q4 NOTE HOLDERS; FILES LATE NOTIFICATION FOR 10Q"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy